| | | CAF14-118 | | California’s Vision for Integrated Climate Action Speakers: Ashley Conrad-Saydah, Deputy Secretary, California Environmental Protection Agency; Raul “JR” DeLaRosa, Assistant Secretary, California Natural Resources Agency; Christina Curry, Deputy Secretary, California’s Office of Emergency Services; Neil Maizlish, Ph.D., Epidemiologist, Climate and Health Team, Office of Equity, California Department of Public Health; MODERATOR: Michael McCormick, Senior Planner and Advisor, Governor’s Office of Planning and Research California’s innovative policies are reducing greenhouse gas emissions and accelerating the transition to a clean-energy economy. At the same time, California is planning and preparing for the unavoidable risks of climate change.The Governor’s Environmental Goals and Policy Report serves as a broad overview for how state efforts work together on a variety of fronts to achieve long-term sustainability. Regarding climate, these efforts fit within an integrated, three-R’s strategy of reducing emissions, climate readiness and research.This strategy is supported by hundreds of agency and department initiatives that ensure long-term implementation of the broader climate change goal and policy framework. Confronting climate change will require unprecedented collaboration across state government and partner organizations and involve nearly every aspect of the state’s planning and investments | | MP3 | | $10.00 | | $10.00 | |
| | | NHF12-103 | | Global Blood Safety, Optimizing Treatment and the Affordability of Care Speakers: Brian O’Mahony, Mark W. Skinner Over the next few years, we will see a revolution in treatment not seen since the 1960s. Treatment products will advance on all fronts, from viral-inactivated (solvent detergent) cryoprecipitate, biosimilars of current therapies and treatment products with substantially enhanced efficacy to the increasing likelihood that through gene transfer a “cure” may become a reality. The blood safety concerns of the past have been replaced by current concerns about maintaining vigilance against such blood-borne agents as viruses and prions. Equally important are the challenges of adequate factor supply and access to products around the world. This session describes how patients have started to join forces to bring all key stakeholders together to ensure that the views of product users are considered when it comes to access to these vital therapies. During this session we also address the challenges of answering US government and payer demands for evidence-based medicine, and cost justification for the introduction of new therapies and enhancement of current treatments. | | MP3 | | $10.00 | | $10.00 | |
